resourceId,resourceName,resourceType,observationText,observationType,observationPhase,observationTime,observationTimeUnits,doi
215b4e43-8a99-4702-ab4b-eeeadeeb13a5,Nf1flox/flox;PostnCre(+),['Animal Model'],The Nf1flox/flox;PostnCre(+) mice develop plexiform neurofibromas in multiple peripheral nerves with 100% penetrance by 4 months of age.,['Tumor incidence'],juvenile,4,months,https://doi.org/10.1002/pbc.28372
215b4e43-8a99-4702-ab4b-eeeadeeb13a5,Nf1flox/flox;PostnCre(+),['Animal Model'],"Early treatment with imatinib mesylate at doses ranging from 10-100 mg/kg/day for 12 weeks starting at 1 month of age prevented initiation of plexiform neurofibromas in the Nf1flox/flox;PostnCre(+) mice, with a 70% reduction in mean number of tumors per animal at the maximum tolerated dose of 100 mg/kg/day.","['Therapeutic response', 'Tumor incidence']",juvenile,1,months,https://doi.org/10.1002/pbc.28372
215b4e43-8a99-4702-ab4b-eeeadeeb13a5,Nf1flox/flox;PostnCre(+),['Animal Model'],"When imatinib treatment was stopped after 12 weeks in Nf1flox/flox;PostnCre(+) mice that received 50 or 100 mg/kg/day starting at 1 month, the number and size of any residual tumors were significantly reduced compared to vehicle controls even 20 weeks after cessation of treatment, demonstrating durable effects.","['Therapeutic response', 'Tumor growth']",juvenile,7,months,https://doi.org/10.1002/pbc.28372
215b4e43-8a99-4702-ab4b-eeeadeeb13a5,Nf1flox/flox;PostnCre(+),['Animal Model'],"The Nf1flox/flox;PostnCre(+) mice were generated by crossing Nf1flox/flox mice with mice expressing Cre recombinase under the control of the Postn (periostin) promoter, resulting in biallelic Nf1 inactivation in cells of the perineural sheath derived from neural crest stem cells.","['Genetics', 'Model development']",,,,https://doi.org/10.1002/pbc.28372
215b4e43-8a99-4702-ab4b-eeeadeeb13a5,Nf1flox/flox;PostnCre(+),['Animal Model'],The Nf1flox/flox;PostnCre(+) mice were genotyped by polymerase chain reaction to confirm their genotypes prior to use in experiments.,"['Genetics', 'Model characterization']",,,,https://doi.org/10.1002/pbc.28372
215b4e43-8a99-4702-ab4b-eeeadeeb13a5,Nf1flox/flox;PostnCre(+),['Animal Model'],Imatinib or vehicle control treatments were administered by daily oral gavage to age and sex-matched cohorts of Nf1flox/flox;PostnCre(+) mice.,['Experimental methods'],,,,https://doi.org/10.1002/pbc.28372
